DORA-22

• Description :

  DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia[1][2].

• UNSPSC :

  12352005

• Target :

  Orexin Receptor (OX Receptor)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/dora-22.html

• Purity :

  97.67

• Smiles :

  FC1=CC(C(N2C[C@H](COC3=NC=C(F)C=C3)CC[C@H]2C)=O)=C(C4=NC=CC=N4)C=C1

• Molecular Formula :

  C23H22F2N4O2

• Molecular Weight :

  424.44

• References & Citations :

  [1]Gamble MC, et al. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020;43 (3) :zsz241. |[2]Lin Y, Ret al. Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice. Front Pharmacol. 2023;14:1138666. Published 2023 Apr 19.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1088991-95-0]